Baker Bros. Advisors SGMT Position
Active3-Fund ConvergenceBaker Bros. Advisors held their position in Sagimet Biosciences Inc. (SGMT) in Q4 2025, holding $5.6M worth of shares across 952,996 shares.
The position was first reported in Q3 2023 and has been tracked across 10 quarterly 13F filings.
SGMT is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 12.8% of float with 9.9 days to cover, indicating significant bearish positioning against Baker Bros.'s long thesis.
About Sagimet Biosciences Inc.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Full company profile →Short Interest
12.8%
9.9 days to cover
Baker Bros. Advisors SGMT Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Held | 952,996 | — | $5.6M |
| Q3 2025 | Held | 952,996 | — | $6.5M |
| Q2 2025 | Held | 952,996 | — | $7.3M |
| Q1 2025 | Held | 952,996 | — | $3.1M |
| Q4 2024 | Decreased | 952,996 | -428,902 | $4.3M |
| Q3 2024 | Held | 1,381,898 | — | $3.8M |
| Q2 2024 | Held | 1,381,898 | — | $4.7M |
| Q1 2024 | Decreased | 1,381,898 | -74,620 | $7.5M |
| Q4 2023 | Increased | 1,456,518 | +641,159 | $7.9M |
| Q3 2023 | New | 815,359 | +815,359 | $7.2M |
Frequently Asked Questions
Does Baker Bros. Advisors own SGMT?
Yes. As of Q4 2025, Baker Bros. Advisors holds 952,996 shares of Sagimet Biosciences Inc. (SGMT) valued at $5.6M. This data comes from their SEC 13F filing.
How many hedge funds own SGMT?
3 specialist biotech hedge funds currently hold SGMT, including Rock Springs Capital, RTW Investments. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Baker Bros. Advisors first buy SGMT?
Baker Bros. Advisors's position in SGMT was first reported in Q3 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Baker Bros. Advisors's SGMT position increasing or decreasing?
Baker Bros. Advisors held their SGMT position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
SGMTCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Baker Bros. AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →